BridgeBio Pharma Cash Flow from Operating Activities 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly cash flow from operating activities history and growth rate from 2018 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
- BridgeBio Pharma cash flow from operating activities for the quarter ending March 31, 2024 was $-0.220B, a 52.12% increase year-over-year.
- BridgeBio Pharma cash flow from operating activities for the twelve months ending March 31, 2024 was $-1.408B, a 30.22% increase year-over-year.
- BridgeBio Pharma annual cash flow from operating activities for 2023 was $-0.528B, a 25.8% increase from 2022.
- BridgeBio Pharma annual cash flow from operating activities for 2022 was $-0.419B, a 15.75% decline from 2021.
- BridgeBio Pharma annual cash flow from operating activities for 2021 was $-0.498B, a 24.57% increase from 2020.
| BridgeBio Pharma Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2023 | $-528 |
| 2022 | $-419 |
| 2021 | $-498 |
| 2020 | $-400 |
| 2019 | $-254 |
| 2018 | $-137 |
| 2017 | $-40 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $5.256B | $0.009B |
| BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $15.763B | 5.69 |
| Dr Reddy's Laboratories (RDY) | India | $12.496B | 19.76 |
| Aspen Pharmacare (APNHY) | South Africa | $5.583B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.758B | 2.10 |
| Amphastar Pharmaceuticals (AMPH) | United States | $2.053B | 14.27 |
| Supernus Pharmaceuticals (SUPN) | United States | $1.672B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $0.490B | 0.00 |
| Generation Bio (GBIO) | United States | $0.223B | 0.00 |
| Personalis (PSNL) | United States | $0.080B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.070B | 0.00 |
| Acasti Pharma (ACST) | Canada | $0.028B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.023B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.004B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |